Needham raised the firm’s price target on Vaxcyte to $140 from $95 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
- Vaxcyte price target raised to $160 from $98 at BTIG
- Morning Movers: U.S. Steel drops after VP Harris opposes sale to Nippon
- Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial
- Vaxcyte reports data from study of VAX-31 vaccine candidate in adults 50+